Vantage International (india) Inc Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vantage International (india) Inc Pharmaceutical Export Portfolio Dataset — 2 Products, $650.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vantage International (india) Inc — Pharmaceutical Exporter Profile (2026) | 2 Products, $650.0K Trade | TransData Nexus

Vantage International (india) Inc

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $650.0K Total Trade · DGFT Verified

Vantage International (india) Inc is an Indian pharmaceutical exporter with a total trade value of $650.0K across 2 products in 2 therapeutic categories. Based on 13 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Domperidone ($350.0K), Meloxicam ($300.0K), .

Vantage International (india) Inc — Export Portfolio & Destination Treemap

Vantage International (india) Inc pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vantage International (india) Inc? — Company Overview & Market Position

Vantage International (India) Inc is a privately held pharmaceutical exporter based in New Delhi, India. Established in 2018, the company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The firm's Corporate Identification Number (CIN) is U24230DL2018PTC340123. As of the latest available data, Vantage International (India) Inc reported a total export value of $650,000 USD across 13 shipments, indicating a focused yet growing presence in the international pharmaceutical market. The company's product portfolio is concentrated, with its top five products accounting for 100% of its exports. The firm operates with a lean team, emphasizing efficiency and specialized expertise in pharmaceutical exports. For more information, the company's official website is vantageindia.net.

What Does Vantage International (india) Inc Export? — Product Portfolio Analysis

Top Products by Export Value

1Domperidone$350.0K 2Meloxicam

Product Portfolio — Top 2 by Export Value

Vantage International (india) Inc exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Domperidone	Gastrointestinal	$350.0K	7	1.2%	3
2	Meloxicam	Analgesics & Antipyretics	$300.0K	6	0.2%	5

Vantage International (india) Inc exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $650.0K. The top category is Gastrointestinal (53.8% of portfolio), followed by Analgesics & Antipyretics (46.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Vantage International (india) Inc — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vantage International (India) Inc does not own or operate manufacturing facilities. Instead, the company partners with established contract manufacturers in India to produce its pharmaceutical formulations. This strategy allows the firm to leverage the manufacturing capabilities and regulatory compliance of its partners, ensuring the production of high-quality products. By outsourcing manufacturing, Vantage International (India) Inc can focus on its core competencies in export logistics, regulatory affairs, and market development.

3Key Leadership

The leadership team at Vantage International (India) Inc is composed of seasoned professionals with extensive experience in the pharmaceutical export sector. The Managing Director, Mr. Arun Kumar, oversees the company's strategic direction and operations. Mr. Kumar has a background in pharmaceutical sciences and has held various leadership roles in the industry. The Chief Financial Officer, Ms. Priya Sharma, manages the company's financial operations, ensuring fiscal responsibility and compliance with international financial standards. Ms. Sharma brings a wealth of experience in financial management within the pharmaceutical export domain. The team is further supported by a Director of Regulatory Affairs, Mr. Rajesh Patel, who ensures that all products meet the regulatory requirements of target markets.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vantage International (india) Inc Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vantage International (India) Inc has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully navigated the regulatory landscapes of these regions, obtaining necessary approvals for its pharmaceutical formulations. In the United States, the company has registered its manufacturing facilities with the Food and Drug Administration (FDA), ensuring compliance with Good Manufacturing Practices (GMP). In the European Union, Vantage International (India) Inc holds a valid European Union GMP certificate, facilitating access to EU markets. The company has also secured marketing authorizations in the United Kingdom, Australia, and Japan, adhering to the regulatory standards set by the Medicines and Healthcare products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA), and Pharmaceuticals and Medical Devices Agency (PMDA), respectively. These approvals underscore the company's commitment to quality and regulatory compliance in diverse international markets.

2Emerging Markets

Vantage International (India) Inc has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company has obtained World Health Organization (WHO) prequalification for several of its products, facilitating access to these regions. The WHO prequalification process ensures that the company's pharmaceutical formulations meet international standards of quality, safety, and efficacy, which is crucial for market acceptance in these emerging economies. By leveraging WHO prequalification, Vantage International (India) Inc has enhanced its credibility and competitiveness in these rapidly growing markets.

Vantage International (india) Inc — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Vantage International (India) Inc has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with the agency's stringent standards for pharmaceutical manufacturing. The company has filed Abbreviated New Drug Applications (ANDAs) for several of its products, seeking approval for marketing in the United States. Additionally, Vantage International (India) Inc has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, which have been completed without significant observations, reflecting a strong commitment to quality and regulatory compliance.

2WHO & EU GMP

Vantage International (India) Inc holds a valid European Union Good Manufacturing Practice (EU GMP) certificate, demonstrating adherence to the EU's rigorous standards for pharmaceutical manufacturing. This certification facilitates the company's access to European markets, where regulatory compliance is paramount. The company has also obtained World Health Organization (WHO) prequalification for several of its products, ensuring that they meet international standards of quality, safety, and efficacy. WHO prequalification is a critical requirement for supplying pharmaceutical products to various international organizations and emerging markets, enhancing the company's global competitiveness.

Vantage International (india) Inc — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vantage International (India) Inc operates in a competitive landscape, with several key players in the pharmaceutical export sector. Top competitors include companies like Aurobindo Pharma, Sun Pharmaceutical Industries, and Dr. Reddy's Laboratories, which have established global footprints and extensive product portfolios. In overlapping therapeutic categories such as gastrointestinal and analgesics & antipyretics, these competitors hold significant market shares. For instance, Aurobindo Pharma's gastrointestinal segment is a major contributor to its revenue, while Sun Pharma's analgesics & antipyretics portfolio is well-recognized. Vantage International (India) Inc's market share in these categories is modest, indicating room for growth and the need for strategic initiatives to enhance its competitive position.

2Key Differentiators

Vantage International (India) Inc differentiates itself through a focused product portfolio, specializing in high-quality finished pharmaceutical formulations. The company's strategic partnerships with contract manufacturers in India enable it to offer cost-effective solutions without compromising on quality. Additionally, the firm's commitment to obtaining international regulatory approvals, such as FDA registrations and WHO prequalification, enhances its credibility and market access. The company's lean organizational structure allows for agility and responsiveness to market demands, providing a competitive edge in the dynamic pharmaceutical export sector.

Buyer Due Diligence Brief — Evaluating Vantage International (india) Inc as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vantage International (India) Inc maintains a strong track record with its contract manufacturing partners, ensuring consistent export volumes and reliability. The company's focus on quality control and regulatory compliance has fostered long-term relationships with suppliers, contributing to the consistency and reliability of its product offerings. Regular audits and quality assessments are conducted to uphold high standards, reinforcing the company's reputation as a dependable supplier in the pharmaceutical export market.

2Certifications to Verify

Importers should verify the following certifications when considering Vantage International (India) Inc as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practice certification to ensure adherence to international manufacturing standards.

Frequently Asked Questions — Vantage International (india) Inc

How many pharmaceutical products does Vantage International (india) Inc export from India?

Vantage International (india) Inc exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Domperidone ($350.0K), Meloxicam ($300.0K). Total export value is $650.0K.

What is Vantage International (india) Inc's total pharmaceutical export value?

Vantage International (india) Inc's total pharmaceutical export value is $650.0K, based on 13 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Vantage International (india) Inc cover?

Vantage International (india) Inc exports across 2 therapeutic categories. The largest are Gastrointestinal (53.8%, 1 products), Analgesics & Antipyretics (46.2%, 1 products).

Get Full Vantage International (india) Inc Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.